The Medical Point Gaziantep Hospital is proud to be the first private hospital in the Southeastern Anatolia Region to establish a Clinical Research Center.
According to the statement, the center will play a critical role in developing new treatments, serving as a hub for groundbreaking research. The center’s operations began with the support of Hayrullah Kubba, Chairman of the Board of Medical Point Hospitals Group, aiming to make these innovations available to patients long before they become standard prescription medications.
‘We are proud to be the first private hospital to establish a Clinical Research Center’
The Clinical Research Center was inaugurated under the leadership of Haluk Gültekin, Deputy General Manager of Medical Point Gaziantep Hospital, and Prof. Dr. Ekber Şahin, Chief Physician and Thoracic Surgery Specialist, with the participation of hospital physicians, administrators, and staff.
Prof. Dr. Ekber Şahin shared, “Our Clinical Research Center at Medical Point Gaziantep Hospital is now established. We plan to achieve great things here with our entire team. We are proud to be the first private hospital in the Southeastern Anatolia Region to establish a Clinical Research Center, aiming to contribute to science by making medications accessible long before they become available on prescription. We are doing our best to be number one in the region.”
‘We Have Received 6 Studies from International Research Centers’
Prof. Dr. Şahin announced that they had received six studies from different centers, covering various areas including skin cancer (malignant melanoma), lung cancer, and bladder cancer. “Patients who qualify will participate in these studies and benefit from the medications. Our center currently has three beds but has the capacity to expand to six. The medications used in our research will eventually become prescription drugs, enabling our patients to access these proven treatments several years earlier. Currently, we focus on cancer-related studies, but we plan to expand our research to include hematological, immunological, and even rheumatological conditions in the future, thereby increasing the center’s service scope and patient intake,” he said.